Matias Serebrinsky

Long gone is the heyday of investor enthusiasm and easy access to capital that marked the launch of the psychedelics industry into the public markets. In recent months, psychedelics stocks entered into a period of turmoil characterized by declining valuations and a generalized capital dry...

A new $25 million venture fund is going all-in on psychedelic medicine. PsyMed is an entrepreneur-led VC fund with a focus on psychedelic medicine, precision psychiatry and neurotechnology. The fund’s goal is to support innovative solutions to solve today’s ongoing mental health...

In a little over one year, the psychedelics industry has experienced exponential growth. With more than 40 public companies and 6 listed on the Nasdaq, investors looking to bet on the “psychedelic renaissance” have a host of alternatives from which to choose.  “In this...